Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Molecular Cancer Therapeutics|October 5, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer ModelsAntje M Wengner, Gerhard Siemeister, Ulrich Lücking, et al.Journal of Medicinal Chemistry|August 24, 2021
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha TherapiesMarkus Berger, Lars Wortmann, Philipp Buchgraber, et al.Journal of Medicinal Chemistry|January 16, 2024
Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839Ulrich Bothe, Judith Günther, Reinhard Nubbemeyer, et al.Journal of Medicinal Chemistry|June 6, 2020
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor ModelsUlrich Lücking, Lars Wortmann, Antje M Wengner, et al.Bioconjugate Chemistry|June 6, 2022
A Novel NAMPT Inhibitor-Based Antibody-Drug Conjugate Payload Class for Cancer TherapyNiels Böhnke, Markus Berger, Nils Griebenow, et al.Chemmedchem|September 30, 2017
Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of CancerUlrich Lücking, Arne Scholz, Philip Lienau, et al.Journal of Medicinal Chemistry|April 28, 2020
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 KinaseVolker K Schulze, Ulrich Klar, Dirk Kosemund, et al.Pageof 2